Previous 10 | Next 10 |
All patients with a complete response (CR) or a partial response (PR) to tab-cel ® alive at one year Overall tab-cel ® survival benefit demonstrated across previous treatment subgroups Phase 2 results validate potential life-saving benefit of treatmen...
Seth Klarman’s 13F portfolio value increased from $10.84B to $12.56B this quarter. Baupost Group increased Alphabet and Intel while reducing Fox Corp and dropping ViacomCBS. They also built small stakes in several SPACs. The portfolio continues to be heavily concentrated wi...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today annou...
JP Morgan has upgraded shares of Atara Biotherapeutics (ATRA) from neutral to overweight based on a physician survey the firm conducted regarding the biotech's phase 1 candidate for multiple sclerosis, ATA188.Analyst Anupam Rama has raised his price target to $29 from $23, implying upside of ...
Palisade Bio (PALI) +36% on FDA's fast track designation for LB1148.Fuel Tech (FTEK) +21% on Q1 results.Lianluo Smart (LLIT) +20%.Celyad Oncology SA (CYAD) +20%.Vertex Energy (VTNR) +18% on Q1 results.InnSuites Hospitality Trust (IHT) +15%.Heron Therapeutics (HRTX) +15% on...
Atara Biotherapeutics (ATRA) announces the appointment of cell therapy and oncology expert Cokey Nguyen as the company's chief scientific officer.Nguyen comes to Atara from Fate Therapeutics, where he held the role of Vice President, Innovation, Research and Development.Sh...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today named c...
Atara Biotherapeutics, Inc. (ATRA) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants Eric Hyllengren – Vice President of Investor Relations and Finance Pascal Touchon – President and Chief Executive Officer Jakob Dupont – Executive Vice Presiden...
Image source: The Motley Fool. Atara Biotherapeutics Inc (NASDAQ: ATRA) Q1 2021 Earnings Call May 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Atara Biotherapeutics Inc (ATRA) Q1 2021 Earnings Call Transcript ...
Atara Biotherapeutics (ATRA): Q1 GAAP EPS of -$0.86 beats by $0.08.Revenue of $3.55M beats by $1.95M.Cash, cash equivalents and short-term investments as of March 31, 2021 totaled $435.2 million, as compared to $500.7 million as of December 31, 2020Atara believes that its cash as of March 31,...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...